Journal
CELL REPORTS
Volume 29, Issue 1, Pages 76-+Publisher
CELL PRESS
DOI: 10.1016/j.celrep.2019.08.076
Keywords
-
Categories
Funding
- Breast Cancer Coalition of Rochester
- King Abdullah International Medical Research Center under the Ministry of National Guard Health Affairs, Saudi Arabia
- NIH [GM122575, CA201402]
Ask authors/readers for more resources
Efforts to target glutamine metabolism for cancer therapy have focused on the glutaminase isozyme GLS. The importance of the other isozyme, GLS2, in cancer has remained unclear, and it has been described as a tumor suppressor in some contexts. Here, we report that GLS2 is upregulated and essential in luminal-subtype breast tumors, which account for >70% of breast cancer incidence. We show that GLS2 expression is elevated by GATA3 in luminal-subtype cells but suppressed by promoter methylation in basal-subtype cells. Although luminal breast cancers resist GLS-selective inhibitors, we find that they can be targeted with a dual-GLS/GLS2 inhibitor. These results establish a critical role for GLS2 in mammary tumorigenesis and advance our understanding of how to target glutamine metabolism in cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available